Lorgia Group

The In Vitro Diagnostics (IVD) Market segment is expanding across multiple diagnostic categories. Clinical chemistry and immunoassays dominate hospital-based labs, while molecular diagnostics and sequencing lead in advanced testing. Point-of-care and rapid diagnostics are expanding the market into non-traditional settings like pharmacies and homes.

Segmentation also extends into disease applications such as oncology, cardiology, infectious diseases, and autoimmune disorders. This diversification ensures that IVD remains a core part of healthcare strategies worldwide. Each segment reflects unique technological needs and growth opportunities, helping companies diversify their portfolios.

FAQsQ1: What are the main IVD segments?Clinical chemistry, immunoassays, molecular, and POC.Q2: Which segment is fastest growing?Molecular diagnostics and rapid testing.Q3: How do disease areas shape segments?They dictate test demand for oncology, infections, etc.Q4: Why are POC tests critical?They expand diagnostics beyond labs.Q5: How do companies benefit from segmentation?It allows diversification across disease categories.